Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.

@article{Bensch2014PhaseII,
  title={Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.},
  author={Frederike Bensch and Laetitia E. Lamberts and Marjolijn N. Lub-de Hooge and Anton G. T. Terwisscha van Scheltinga and Johan R. de Jong and Jourik A. Gietema and Carolien P. Schröder and Michiel M. Smeenk and Wolfgang Jacob and K. R. Abiraj and Michael K. Wolf and C{\'e}line Adessi and Georgina Meneses‐Lorente and Magdalena Zając and Martin Weisser and Adrienne H. Brouwers and Elisabeth G. E. de Vries},
  journal={Journal of Clinical Oncology},
  year={2014},
  volume={32},
  pages={11095-11095}
}
11095 Background: Human epidermal growth factor receptor 3 (HER3) can play a critical role in tumor growth, proliferation and progression. The glycoengineered humanized monoclonal HER3-targeting antibody RG7116 is currently in phase I development (NCT01482377). Knowledge about whole body target expression, drug biodistribution and organ pharmacokinetics is lacking from many phase I designs. The aim of this imaging study is to determine in vivo biodistribution and tumor targeting characteristics… 
Human Epidermal Growth Factor Receptor 3–Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging
TLDR
Ex vivo biodistribution showed protein dose– and time-dependent distribution of 89Zr-MSB0010853 in all organs, and tumor uptake correlates with HER3 expression, which is in contrast to tumor uptake except for kidney uptake.
Antibody positron emission tomography imaging in anticancer drug development.
TLDR
This approach could potentially increase the power and value of early trials by improving patient selection, optimizing dose and schedule, and rationalizing observed drug responses.
Molecular imaging in ovarian cancer.
TLDR
Molecular imaging can capture data on intra-patient tumor heterogeneity and is of potential value for individualized, target-guided treatment selection in patients with ovarian cancer.
University of Groningen Antibody imaging as biomarker in early cancer drug development and treatment
TLDR
The technology has great potential to inform decisions in early clinical development by addressing fundamental questions of drug delivery, dose finding, and target modulation, thereby prioritizing the right agents.
Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients
TLDR
Developing of EGFR imaging with fluorescence and address preclinical imaging results in HNSCC models for other molecular targets, including integrin αvβ3 are addressed.
Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds
TLDR
An overview of specific protein properties and modifications that can affect biodistribution and tumor uptake of anticancer antibodies, antibody fragments, and nonimmunoglobulin scaffolds is provided.
University of Groningen Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of Zr-89-MSB 0010853 Visualized by Real-Time and Noninvasive PET Imaging
TLDR
Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of Zr-89-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging.
Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications
TLDR
This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membrane‐coated nanoparticles, tumor cell‐derived extracellular vesicles, circulating tumor cells, cell‐free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology‐based imaging probes in the future.